1. Pink Sheet
  2. >>Pathways & Standards

Intercept’s Ocaliva: ‘Dangling’ PBC Indication At Risk As Near-Term NASH Approval Looks Unlikely

 
• By Sue Sutter

Accelerated approval for primary biliary cholangitis in 2016 came with three postmarketing requirements, but studies were terminated early; firm working toward sNDA submission in 2023 for regular approval, but US FDA says reports already are overdue and it expects to take PBC indication back to an adcomm.

Dangling shoes
Ocaliva appears to fit FDA's definition of a 'dangling' accelerated approval - when prespecified postmarketing trials do not confirm benefit but marketing continues. • Source: Shutterstock

With the prospects for near-term approval of Intercept Pharmaceuticals, Inc.’s obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH) fibrosis considerably dimmed by a negative FDA review and advisory committee recommendation, the drug’s existing accelerated approval in a much smaller indication also may be at risk for lack of confirmation of clinical benefit after seven years on the market.

The postmarketing studies required under OCA’s 2016 accelerated approval in primary biliary cholangitis were terminated prior to completion due to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Review Pathways

More from Pathways & Standards

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.

Elegy For SACHRP: US HHS Research Protection Panel Tackled Tough Pediatric Trial Questions

 
• By Bridget Silverman

The termination of the HHS Secretary’s Committee on Human Research Protections closed an important forum for discussing pediatrics and pregnancy in clinical trial design, a former SACHRP chair said.